

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-45 (Canceled).

Claim 46 (New): A method for inhibiting the formation of metastases in treatment of colon carcinoma, colorectal carcinoma, pancreas carcinoma, prostate cancer or melanoma in a subject comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of: SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48 to a subject, wherein said at least one oligonucleotide inhibits the formation of metastases in said subject.

Claim 47 (New): The method of claim 46, wherein said cancer is colon carcinoma.

Claim 48 (New): The method of claim 46, wherein said cancer is pancreas carcinoma.

Claim 49 (New): The method of claim 46, wherein said cancer is melanoma.

Claim 50 (New): The method of claim 46, wherein said TGF-beta2 antisense oligonucleotide is SEQ ID NO: 35.

Claim 51 (New): A method of cancer treatment comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48 to a subject, wherein said at least one TGF-beta2 antisense oligonucleotide inhibits the formation of metastases in said subject and said cancer is selected from the group consisting of prostate cancer, colon cancer, pancreatic cancer, melanoma and colorectal carcinoma.

Claim 52 (New): A method for cancer metastasis treatment comprising the step of administering at least one TGF-beta2 antisense oligonucleotide selected from the group consisting of SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48 to a subject, wherein said cancer is selected from the group consisting of prostate cancer, colon cancer, pancreatic cancer, melanoma and colorectal carcinoma.